Tag: Aquavit Pharmaceuticals

All

Aquavit Pharmaceuticals, Inc. has submitted to the U.S. FDA an Investigation of New Drug package for a new botulinum toxin, DTX-021.

The tabletop system builds on the UltraClear platform with multiple treatment modes targeting pigment, texture, and scarring across skin types.